What's Happening?
Bayer's drug Kerendia, a mineralocorticoid receptor antagonist, has demonstrated positive results in a phase 3 trial aimed at treating chronic kidney disease (CKD) in patients without diabetes. The FIND-CKD study, which included 1,500 participants, showed
that adding Kerendia to standard treatment reduced the rate of kidney function decline compared to a placebo. This development is significant as CKD affects approximately 850 million people globally, with many cases not linked to diabetes but to other conditions like high blood pressure. Bayer is focusing on extending Kerendia's label to include non-diabetic CKD patients, which could help the company offset declining sales of other drugs like Xarelto and Eylea.
Why It's Important?
The findings from the FIND-CKD study could have substantial implications for the treatment of CKD, particularly for patients who do not have diabetes. This group is at a higher risk of cardiovascular events and kidney failure, which often leads to dialysis—a treatment with a low five-year survival rate. By potentially slowing the progression of kidney disease, Kerendia could improve patient outcomes and reduce the need for dialysis. For Bayer, expanding Kerendia's use is a strategic move to bolster its product lineup amid patent expirations and competitive pressures on other drugs. The company anticipates that Kerendia could eventually generate over $3 billion in annual sales.
What's Next?
Bayer plans to present the full data from the FIND-CKD study at an upcoming scientific conference and intends to file for an extension of Kerendia's label based on these results. The company is conducting a comprehensive 10-study phase 3 program for Kerendia, with FIND-CKD being the fifth to yield positive outcomes. As Bayer continues to invest in Kerendia's development, the drug could become a cornerstone of its strategy to maintain growth in the pharmaceutical market.
